OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Advancing the Science of Pharmaceutical Manufacturing
Collaboration and new tools aid efforts to implement new processing technologies for small-molecule drug product manufacturing.
Experts discuss what data to consider when selecting a high-potential drug candidate.
Effective cleaning and disinfection along with contamination controls is imperative when operating and utilizing a cleanroom.
Data may be used to improve (or remove) a corrective action/preventive action.
The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.
Biologic Drug Development and Manufacturing
May 27, 2022
Foxx Life Sciences and Thomas Scientific collaborate to simplify online ordering access to Foxx’s media bottle assembly offerings.
May 26, 2022
Dupixent (dupilumab), developed by Regeneron Pharmaceuticals in partnership with Sanofi, has received FDA approval for a new indication—treating eosinophilic esophagitis, a chronic inflammatory disease.
Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.
AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.
Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.
May 24, 2022
AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.
Sferalp will use Fluid Air’s PolarDry technology for powder processing.
A new initiative aims to speed the approval of and access to new drugs for young patients around the world, while limiting the number of children needed for testing in clinical trials.
AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.
EMA has recommended the marketing authorization of Xenpozyme (olipudase alfa) in the European Union.